Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Molecular Oncology|July 28, 2023
Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancerOfra Novoplansky, Avital B Shnerb, Divyasree Marripati, et al.
Cancers|April 12, 2022
Unmet Needs and Perspectives in Oral Cancer PreventionJebrane Bouaoud, Paolo Bossi, Moshe Elkabets, et al.
International Journal of Molecular Medicine|March 4, 2016
Streptococcus pneumoniae fructose-1,6-bisphosphate aldolase, a protein vaccine candidate, elicits Th1/Th2/Th17-type cytokine responses in miceShirin Elhaik Goldman, Shahar Dotan, Amir Talias, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|June 19, 2024
Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for GlioblastomaXin Peng, Xin Huang, Shaolu Zhang, et al.
Neoplasia (New York, N.Y.)|March 21, 2025
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancersDinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, et al.
NPJ Precision Oncology|May 23, 2024
Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancerThomas F Cyberski, Alka Singh, Michael Korzinkin, et al.
Advanced Materials (Deerfield Beach, Fla.)|May 10, 2025
Mechanostimulatory Platform for Improved CAR T Cell ImmunotherapyAbed Al-Kader Yassin, Carlos Ureña Martin, Guillaume Le Saux, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Oral Oncology|January 14, 2024
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinomaSankar Jagadeeshan, Kushal Suryamohan, Nara Shin, et al.
Pageof 9